Literature DB >> 33508058

Current advances in drug delivery of nanoparticles for respiratory disease treatment.

Beatriz Rossi Canuto de Menezes1, Karla Faquine Rodrigues1, Vanessa Modelski Schatkoski1, Raíssa Monteiro Pereira1, Renata Guimarães Ribas1, Thaís Larissa do Amaral Montanheiro1, Gilmar Patrocínio Thim1.   

Abstract

Cases of respiratory diseases have been increasing around the world, affecting the health and quality of life of millions of people every year. Chronic respiratory diseases (CRDs) and acute respiratory infections (ARIs) are responsible for many hospital admissions and deaths, requiring sophisticated treatments that facilitate the delivery of therapeutics to specific target sites with controlled release. In this context, different nanoparticles (NPs) have been explored to match this demand, such as lipid, liposome, protein, carbon-based, polymeric, metallic, oxide, and magnetic NPs. The use of NPs as drug delivery systems can improve the efficacy of commercial drugs due to their advantages related to sustained drug release, targeting effects, and patient compliance. The current review presents an updated summary of recent advances regarding the use of NPs as drug delivery systems to treat diseases related to the respiratory tract, such as CRDs and ARIs. The latest applications presented in the literature were considered, and the opportunities and challenges of NPs in the drug delivery field are discussed.

Entities:  

Mesh:

Substances:

Year:  2021        PMID: 33508058     DOI: 10.1039/d0tb01783c

Source DB:  PubMed          Journal:  J Mater Chem B        ISSN: 2050-750X            Impact factor:   6.331


  3 in total

Review 1.  Emerging strategies in nanotechnology to treat respiratory tract infections: realizing current trends for future clinical perspectives.

Authors:  Minhua Chen; Zhangxuan Shou; Xue Jin; Yingjun Chen
Journal:  Drug Deliv       Date:  2022-12       Impact factor: 6.819

2.  Co-delivery of sorafenib and crizotinib encapsulated with polymeric nanoparticles for the treatment of in vivo lung cancer animal model.

Authors:  Tian Zhong; Xingren Liu; Hongmin Li; Jing Zhang
Journal:  Drug Deliv       Date:  2021-12       Impact factor: 6.819

Review 3.  Nanoparticles as therapeutic options for treating multidrug-resistant bacteria: research progress, challenges, and prospects.

Authors:  Ifeanyi E Mba; Emeka I Nweze
Journal:  World J Microbiol Biotechnol       Date:  2021-05-28       Impact factor: 3.312

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.